ClinicalTrials.gg
CompletedNCT03444766Updated Dec 4, 2020Results posted

Study of Nivolumab for Advanced Cancers in India

A Phase 4 interventional study of Nivolumab in Non-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma and Nonsmall Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 9 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-04.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
45th of 120
100 · median 66
Started
2018
with 14 others
Phase 4
2 of 120
none open now
Registered
62nd of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 45th largest by enrollment, is one of 15 that started in 2018, is one of 2 in phase 4, and was the 62nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)
  • Non-Small-Cell Lung Carcinoma
  • Nonsmall Cell Lung Cancer
  • Kidney Cancer
  • Kidney Neoplasms
  • Renal Cancer
  • Renal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Locally advanced or non-small cell lung cancer (NSCLC) after prior chemotherapy OR advanced renal cell carcinoma (RCC) after prior therapy
  • (ECOG) performance status of ≤ 1
  • Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Participants with untreated, symptomatic central nervous system (CNS)
  • Participants with carcinomatous meningitis
  • Participants with active, known or suspected disease
  • Participants with a condition requiring systemic treatment with either or other medications
  • Other active requiring concurrent intervention

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Monotherapy

    administering nivolumab only

    Drug: Nivolumab

Interventions

  • specified dose on specified days

    Also known as: Opdivo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events

    Number of participants with treatment-related Adverse Events based on worst ctc grade Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

    Time frame: 26 Weeks

Secondary outcomes

  1. Number of Participants With Treatment-related Select Adverse Events

    Number of participants with treatment-related Select Adverse Events based on worst ctc grade for the following categories: Pulmonary, Gastrointestinal, Endocrinopathies, Hepatic, Renal, Skin, Neurological and Hypersensitivity/Infusion reactions Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

    Time frame: 26 Weeks

  2. Number of Participants With Treatment-related Serious Adverse Events

    Number of participants with treatment-related Serious Adverse Events based on worst CTC grade Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

    Time frame: 26 Weeks

  3. Number of Participants With Adverse Events Leading to Discontinuation

    Number of participants with Adverse events leading to discontinuation of treatment based on worst CTC grade Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

    Time frame: 26 Weeks

07

Results

Posted Dec 4, 2020

Participant flow

Participant flow — Overall Study
MilestoneNivolumab
Started100
Completed34
Not completed66
Withdrew: Other reasons2
Withdrew: Participant withdrew consent5
Withdrew: Lost to follow-up2
Withdrew: Death2
Withdrew: Adverse event unrelated to study drug6
Withdrew: Disease progression49

Outcome measures

PrimaryNumber of Participants With Treatment-related Adverse Events

Number of participants with treatment-related Adverse Events based on worst ctc grade Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

Time frame:
26 Weeks
Reported as:
Number · Count of participants
Number of Participants With Treatment-related Adverse Events
Count of participantsNivolumab
Any Grade25
Grade 3-44
Grade 51
SecondaryNumber of Participants With Treatment-related Select Adverse Events

Number of participants with treatment-related Select Adverse Events based on worst ctc grade for the following categories: Pulmonary, Gastrointestinal, Endocrinopathies, Hepatic, Renal, Skin, Neurological and Hypersensitivity/Infusion reactions Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

Time frame:
26 Weeks
Reported as:
Number · Count of participants
Number of Participants With Treatment-related Select Adverse Events
Count of participantsNivolumab
Pulmonary (Grade 3)1
Pulmonary (Grade 5)1
Hepatic (Grade 1)1
Skin (Grade 1)2
Hypersensitivity/Infusion reaction (Grade 1)1
Hypersensitivity/Infusion reaction (Grade 2)2
SecondaryNumber of Participants With Treatment-related Serious Adverse Events

Number of participants with treatment-related Serious Adverse Events based on worst CTC grade Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

Time frame:
26 Weeks
Reported as:
Number · Count of participants
Number of Participants With Treatment-related Serious Adverse Events
Count of participantsNivolumab
Any Grade4
Grade 3 - 43
Grade 51
SecondaryNumber of Participants With Adverse Events Leading to Discontinuation

Number of participants with Adverse events leading to discontinuation of treatment based on worst CTC grade Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

Time frame:
26 Weeks
Reported as:
Number · Count of participants
Number of Participants With Adverse Events Leading to Discontinuation
Count of participantsNivolumab
Grade 17
Grade 25
Grade 39
Grade 40
Grade 51

Adverse events

Collected over 26 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab17/100 (17%)30/100 (30%)74/100 (74%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventNivolumab
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/100
AstheniaGeneral disorders3/100
DyspnoeaRespiratory, thoracic and mediastinal disorders3/100
Cardiac arrestCardiac disorders2/100
HeadacheNervous system disorders2/100
PneumonitisRespiratory, thoracic and mediastinal disorders2/100
Respiratory failureRespiratory, thoracic and mediastinal disorders2/100
Abdominal painGastrointestinal disorders1/100
Intestinal obstructionGastrointestinal disorders1/100
PyrexiaGeneral disorders1/100
Most frequent other events
Showing 10 of 20
Most frequent other events
EventNivolumab
CoughRespiratory, thoracic and mediastinal disorders24/100
PyrexiaGeneral disorders21/100
VomitingGastrointestinal disorders17/100
FatigueGeneral disorders16/100
DyspnoeaRespiratory, thoracic and mediastinal disorders14/100
Back painMusculoskeletal and connective tissue disorders13/100
NauseaGastrointestinal disorders11/100
Chest painGeneral disorders11/100
Decreased appetiteMetabolism and nutrition disorders11/100
HeadacheNervous system disorders11/100

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Nivolumab
Mean54.7 ± 10.79
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab
Female22
Male78
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported100
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab
American Indian or Alaska Native0
Asian100
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

9 sites
  • Local Institution
    Bangalore, 560027, India
  • Local Institution
    Bangalore, 560072, India
  • Local Institution
    Bengaluru, 560054, India
  • Local Institution
    Hyderabad, 500034, India
  • Local Institution
    Jaipur, 302004, India
  • Local Institution
    Kolkata, 700156, India
  • Local Institution
    Mumbai, 400012, India
  • Local Institution
    New Delhi, 110029, India
  • Local Institution
    Vellore, 632004, India
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jul 2019, 16 months.

Results were first posted in Dec 2020, 1 year 4 months after primary completion.

Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2018
First posted
Feb 23, 2018
StartActual
Mar 6, 2018
Primary completionActual
Jul 17, 2019
CompletionActual
Jul 17, 2019
Results first posted
Dec 4, 2020
Last update
Dec 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03444766
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Mar 6, 2018
Primary completion
Jul 17, 2019
Completion
Jul 17, 2019
Results posted
Dec 4, 2020
Last update
Dec 4, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion